Pravastatin
Based on 9 publication(s) in Google Scholar
Pravastatin (CS-514) is a competitive HMG-CoA reductase inhibitor against sterol synthesis with IC50 of 5.6 μM.
For research use only. We do not sell to patients.
- CAS No.: 81093-37-0
- Formula: C23H36O7
- Molecular Weight:424.53
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) Pravastatin
More- Phytother Res. 2026 Mar 26. [Abstract]
- Cell Syst. 2018 Apr 25;6(4):424-443.e7. [Abstract]
- Front Cell Dev Biol. 2022 Mar 3;10:806081. [Abstract]
- Front Cell Dev Biol. 2020 May 28:8:404. [Abstract]
- FASEB J. 2026 May 15;40(9):e71873. [Abstract]
- Chin J Integr Med. 2024 Oct;30(10):896-905. [Abstract]
- FEBS Open Bio. 2025 Aug 8. [Abstract]
- bioRxiv. 2026 May 22.
- Research Square Preprint. 2022 Feb.
-
Cell Proliferation/Viability Assay
-
RT-PCR
-
RT-PCR
-
Cell Imaging/Staining
-
Cell Proliferation/Viability Assay
Biological Activity
Description
IC50 & Target
HMG-CoA reductase[1]
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
190 μM
Compound: Pravastatin
|
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake incubated for 5 mins by scintillation counting
|
[PMID: 22541068] |
| HEK293 | IC50 |
3.6 μM
Compound: Pravastatin
|
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake by scintillation counting
|
[PMID: 22541068] |
| HEK293 | IC50 |
62 μM
Compound: Pravastatin
|
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake incubated for 5 mins by scintillation counting
|
[PMID: 22541068] |
| Hepatocyte | IC50 |
17 nM
Compound: pravastatin
|
Inhibition of cholesterol synthesis in rat hepatocytes
Inhibition of cholesterol synthesis in rat hepatocytes
|
[PMID: 18072721] |
| Hepatocyte | IC50 |
17 nM
Compound: pravastatin
|
Inhibition of cholesterol synthesis in rat hepatocyte
Inhibition of cholesterol synthesis in rat hepatocyte
|
[PMID: 18155906] |
| Hepatocyte | IC50 |
29 nM
Compound: pravastatin
|
Inhibition of cholesterol synthesis in rat hepatocytes assessed as incorporation of [14C]acetate into cholesterol
Inhibition of cholesterol synthesis in rat hepatocytes assessed as incorporation of [14C]acetate into cholesterol
|
[PMID: 18412317] |
| HepG2 | IC50 |
>10 μM
Compound: Pravastatin
|
In vitro ability to inhibit cholesterol biosynthesis in HepG2 cells in culture from [14C]mevalonate
In vitro ability to inhibit cholesterol biosynthesis in HepG2 cells in culture from [14C]mevalonate
|
[PMID: 7650673] |
| HepG2 | IC50 |
0.43 μM
Compound: Pravastatin
|
In vitro ability to inhibit cholesterol biosynthesis in HepG2 cells in culture from [14C]acetate
In vitro ability to inhibit cholesterol biosynthesis in HepG2 cells in culture from [14C]acetate
|
[PMID: 7650673] |
| HepG2 | IC50 |
5100 nM
Compound: Pravastatin
|
In vitro inhibitory activity was evaluated on cholesterol biosynthesis in HepG2 cells
In vitro inhibitory activity was evaluated on cholesterol biosynthesis in HepG2 cells
|
[PMID: 14741258] |
| L6 | IC50 |
1519 nM
Compound: pravastatin
|
Inhibition of cholesterol synthesis in rat L6 cells assessed as incorporation of [14C]acetate into cholesterol
Inhibition of cholesterol synthesis in rat L6 cells assessed as incorporation of [14C]acetate into cholesterol
|
[PMID: 18412317] |
| L6 | IC50 |
7550 nM
Compound: pravastatin
|
Inhibition of cholesterol synthesis in rat L6 myocyte
Inhibition of cholesterol synthesis in rat L6 myocyte
|
[PMID: 18155906] |
| L6 | IC50 |
7600 nM
Compound: pravastatin
|
Inhibition of cholesterol synthesis in rat L6 cells
Inhibition of cholesterol synthesis in rat L6 cells
|
[PMID: 18072721] |
| S2 | IC50 |
13.7 μM
Compound: Pravastatin
|
TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in hOAT3-expressing S2 cells
TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in hOAT3-expressing S2 cells
|
[PMID: 14978359] |
| S2 | IC50 |
15.6 μM
Compound: Pravastatin
|
TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in rOAT3-expressing S2 cells
TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in rOAT3-expressing S2 cells
|
[PMID: 14978359] |
| S2 | IC50 |
352 μM
Compound: Pravastatin
|
TP_TRANSPORTER: inhibition of PGF2alpha uptake (PGF2: 50nM) in hOAT2-expressing S2 cells
TP_TRANSPORTER: inhibition of PGF2alpha uptake (PGF2: 50nM) in hOAT2-expressing S2 cells
|
[PMID: 14978359] |
| S2 | IC50 |
408 μM
Compound: Pravastatin
|
TP_TRANSPORTER: inhibition of PHA uptake (PHA: 5uM) in hOAT1-expressing S2 cells
TP_TRANSPORTER: inhibition of PHA uptake (PHA: 5uM) in hOAT1-expressing S2 cells
|
[PMID: 14978359] |
| S2 | IC50 |
449 μM
Compound: Pravastatin
|
TP_TRANSPORTER: inhibition of PGF2alpha uptake (PGF2: 50nM) in rOAT2-expressing S2 cells
TP_TRANSPORTER: inhibition of PGF2alpha uptake (PGF2: 50nM) in rOAT2-expressing S2 cells
|
[PMID: 14978359] |
| S2 | IC50 |
591 μM
Compound: Pravastatin
|
TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in hOAT4-expressing S2 cells
TP_TRANSPORTER: inhibition of ES uptake (ES: 50nM) in hOAT4-expressing S2 cells
|
[PMID: 14978359] |
In Vitro
Pravastatin (CS-514) is a member of the drug class of statins, used in combination with diet, exercise, and weight-loss for lowering cholesterol and preventing cardiovascular disease[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 81093-37-0
-
Appearance Solid
-
Molecular Weight 424.53
-
Formula C23H36O7
-
Color Off-white to light yellow
-
SMILES
O[C@@H](C[C@@H](O)CC(O)=O)CC[C@@H]([C@H](C=C1)C)[C@@](C1=C[C@@H](O)C2)([H])[C@H]2OC([C@@H](C)CC)=O
-
Synonyms
CS-514
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Phytother Res
Syringin Protects Against Doxorubicin-Induced Cardiotoxicity via Apelinr-Dependent Activation of the Nuclear Factor-Erythroid 2-Related Factor 2/Heme Oxygenase-1 Antioxidant Pathway. [Abstract]2026 Mar 26. PMID: 41883153 -
Cell Syst
A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]2018 Apr 25;6(4):424-443.e7. PMID: 29655704 -
Front Cell Dev Biol
Atorvastatin Induces Mitochondria-Dependent Ferroptosis via the Modulation of Nrf2-xCT/GPx4 Axis. [Abstract]2022 Mar 3;10:806081. PMID: 35309902 -
Front Cell Dev Biol
Construction of Escherichia coli Whole-Cell Biosensors for Statin Efficacy and Production Test. [Abstract]2020 May 28:8:404. PMID: 32671060 -
FASEB J
Simvastatin Restores Cisplatin Sensitivity by Suppressing the Caveolin-1-Mediated PI3K/AKT Signaling Pathway in Cisplatin-Resistant Cervical Cancer Cells. [Abstract]2026 May 15;40(9):e71873. PMID: 42087353 -
Chin J Integr Med
Treg Immunomodulation Contributes to the Anti-atherosclerotic Effects of Huxin Formula in ApoE-/- Mice. [Abstract]2024 Oct;30(10):896-905. PMID: 38753277 -
FEBS Open Bio
Statins induce monocytic differentiation in acute myeloid leukemia cells through the KLF4/DPYSL2A axis. [Abstract]2025 Aug 8. PMID: 40781787
Pravastatin purchased from MedChemExpress. Usage Cited in: FEBS Open Bio. 2025 Aug 8. [Abstract]
Growth inhibition following statin treatment of THP‐1 cells. To assess cell proliferation, 1 × 104 cells were seeded in a six‐well plate and cultured with DMSO or Pravastatin (2 or 4 μM). Trypan blue dye exclusion assays were performed after 6 days of treatment (n = 4).
Pravastatin purchased from MedChemExpress. Usage Cited in: FEBS Open Bio. 2025 Aug 8. [Abstract]
Relative mRNA expression levels of KLF4 and DPYSL2A in THP‐1 cells treated by Pravastatin (2 or 4 μM). Total RNA was then extracted and analyzed by RT‐qPCR. Values were normalized to the GAPDH expression levels (n = 3).
Pravastatin purchased from MedChemExpress. Usage Cited in: FEBS Open Bio. 2025 Aug 8. [Abstract]
Cell surface expression levels of CD11b and CD14 in THP‐1 cells treated Pravastatin (2 or 4 μM) (n = 3).
Pravastatin purchased from MedChemExpress. Usage Cited in: FEBS Open Bio. 2025 Aug 8. [Abstract]
Morphological changes in THP‐1 cells treated with DMSO or Pravastatin (4 μM) for 6 days.
Pravastatin purchased from MedChemExpress. Usage Cited in: FEBS Open Bio. 2025 Aug 8. [Abstract]
Apoptosis of THP‐1 cells treated Pravastatin (2 or 4 μM). The annexin V‐positive cells were scored using flow cytometric analysis (n = 3).
-
-
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)